Bristol Myers Squibb (CELG-RI) Long-Term Deferred Tax (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Long-Term Deferred Tax of $5.4 billion for Q2 2026, up 15.39% year-over-year from $4.6 billion in Q2 2025, and up 3.59% quarter-over-quarter from $5.2 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Long-Term Deferred Tax (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Long-Term Deferred Tax for 18 consecutive years, with $5.4 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Long-Term Deferred Tax rose 15.39% year-over-year to $5.4 billion; the TTM figure through Jun 2026 stood at $5.4 billion (up 15.39% YoY), while the FY2025 annual figure was $5.4 billion, up 26.96% from the prior year.
- Long-Term Deferred Tax rose to $5.4 billion in Q2 2026 per CELG-RI's latest filing, from $5.2 billion in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $5.4 billion in Q4 2025 and bottomed at $1.3 billion in Q1 2023.
- Historically, Long-Term Deferred Tax has averaged $3.1 billion across 5 years, with a median of $3.0 billion in 2023.
- Annual changes were most pronounced in 2023 — Long-Term Deferred Tax slipped 7.12% — and 2024, when it surged 138.38%.
- Bristol Myers Squibb's Long-Term Deferred Tax stood at $1.3 billion in 2022, then soared by 105.95% to $2.8 billion in 2023, then soared by 53.03% to $4.2 billion in 2024, then climbed by 26.96% to $5.4 billion in 2025, then decreased by 0.3% to $5.4 billion in 2026.
- Business Quant data shows CELG-RI's Long-Term Deferred Tax at $5.4 billion in Q2 2026, $5.2 billion in Q1 2026, and $5.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.36 Bn |
| Mar 31, 2026 | 5.18 Bn |
| Dec 31, 2025 | 5.38 Bn |
| Sep 30, 2025 | 4.96 Bn |
| Jun 30, 2025 | 4.65 Bn |
| Mar 31, 2025 | 4.00 Bn |
| Dec 31, 2024 | 4.24 Bn |
| Sep 30, 2024 | 3.61 Bn |
| Jun 30, 2024 | 3.32 Bn |
| Mar 31, 2024 | 2.72 Bn |
| Dec 31, 2023 | 2.77 Bn |
| Sep 30, 2023 | 1.51 Bn |
| Jun 30, 2023 | 1.57 Bn |
| Mar 31, 2023 | 1.32 Bn |
| Dec 31, 2022 | 1.34 Bn |
| Sep 30, 2022 | 1.33 Bn |
| Jun 30, 2022 | 1.34 Bn |
| Mar 31, 2022 | 1.42 Bn |
| Dec 31, 2021 | 1.44 Bn |
| Sep 30, 2021 | 684.00 Mn |